Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centresTrial will validate the use of CLEO’s ovarian cancer…
She emphasized that a global perspective is key for understanding these metals as geopolitical turmoil unfolds. ‘I think the…
ChemX Materials (ASX:CMX) (ChemX or the Company), an Australian high purity critical materials company and 100%-owner of the HiPurA®…
Investor Insight A Bloomberg Intelligence report shows the plant-based market could make up to 7.7 percent of the global…
Right place, right time, right geology: Graham Arvidson believes Australia has a unique opportunity to build a world-class vanadium…
G Mining Ventures (TSX:GMIN,OTC Pink:GMINF) announced on Tuesday (September 3) that it has started commercial production at its Brazil-based…
(TheNewswire) Drilling indicates the presence of a Carbonate Replacement (‘CRD’) style system at Tim 2,252 metres drilled in six…
Chilean state-run copper giant Codelco has made a US$500 million bid to acquire a 10 percent stake in the…
True North Copper Limited (ASX:TNC) (True North, TNC or the Company) is pleased to announce results from a systematic…